Objective
to compare safety and efficacy of a new third-generation sirolimus-eluting stent system with bioresorbable polymer (Orsiro) compared with an everolimus-eluting stent system with permanent polymer (XIENCE)
Study
prospective, international, multicentre, 2:1 randomised, non-inferiority trial
Population
patients with stable CAD or ACS (not STEMI) and de novo lesions in â¤2 vessels
Endpoints
target vessel failure at 12 months
Conclusion
Orsiro SES was non-inferior to XIENCE EES at 12 months
Saito et al. EuroIntervention. 2019;15:e1006-13